Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07695701 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

Study acronym: ASCEND-ATTR
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Study sites: 0 to 1 · Secondary endpoints: details revised at 1 of 5 entries · Study description expanded, about 2 wordsv2 Show 3 more changesShow less
    • Study sites: 0 to 1
    • Secondary endpoints: details revised at 1 of 5 entries
    • Study description expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.
Trial Details
NCT Number NCT07695701
Lead Sponsor Eidos Therapeutics, a BridgeBio company
Conditions Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov